GeNeuro (FRA:GEM) Other Financing: €-0.04 Mil (TTM As of Dec. 2023)


FRA:GEM GeNeuro SA FRA:GEM
8 GF Score
Price €0.03
View Full Analysis

What is GeNeuro Other Financing?

GeNeuro FRA:GEM 8 Other Financing is €-0.04 Mil as of Dec. 2023. GuruFocus rates FRA:GEM with a GF Score™ of 8/100.

GeNeuro's Other Financing for the six months ended in Dec. 2023 was €-0.02 Mil.

GeNeuro's Other Financing for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.04 Mil.

GeNeuro Other Financing Historical Data

* Premium members only.

The historical data trend for GeNeuro's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GeNeuro Other Financing Chart

GeNeuro Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.25 -1.44 -0.45 -0.65 -0.04

GeNeuro Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.60 -0.64 -0.01 -0.02 -0.02
FRA:GEM
8GF Score
GeNeuro SA FRA:GEM
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GeNeuro Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €-0.04 Mil mean?
GeNeuro (FRA:GEM) has a Other Financing of €-0.04 Mil as of Dec. 2023. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for GeNeuro and its competitors.
Is GeNeuro's Other Financing too high?
GeNeuro's current Other Financing is €-0.04 Mil. Overall, GeNeuro has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does GeNeuro's Other Financing compare to VRTX and REGN?
GeNeuro's Other Financing of €-0.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for GeNeuro and its competitors. GeNeuro's current Other Financing is €-0.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeNeuro stock overvalued right now?
GeNeuro (FRA:GEM) has a current Other Financing of €-0.04 Mil. The current Other Financing is €-0.04 Mil. GeNeuro's overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For GeNeuro (FRA:GEM), the current Other Financing is €-0.04 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GeNeuro Business Description

Address 3 chemin du Pre-Fleur, Plan-les-Ouates, Geneva, CHE, 1228
GeNeuro SA is a clinical-stage biopharmaceutical company focused on understanding and stopping causal factors driving the progression of neurodegenerative and autoimmune diseases. The company's therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family (W-ENV).
8GF Score

Get the complete analysis for FRA:GEM

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.03
Price